{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:49Z","timestamp":1792787869778,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Besins Healthcare"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-03587-5","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T04:23:02Z","timestamp":1740198182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The impact of progestogens on RAAS \u2013 a systematic review"],"prefix":"10.1186","volume":"25","author":[{"given":"Adrian","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Tropschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"von Gernler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Decrinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"21","key":"3587_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM198511213132106","volume":"313","author":"JS Flier","year":"1985","unstructured":"Flier JS, Underhill LH, Laragh JH. Atrial natriuretic hormone, the renin\u2013aldosterone Axis, and blood pressure\u2013Electrolyte Homeostasis. N Engl J Med. 1985;313(21):1330\u201340. https:\/\/doi.org\/10.1056\/NEJM198511213132106.","journal-title":"N Engl J Med"},{"issue":"77","key":"3587_CR2","doi-asserted-by":"publisher","first-page":"34628","DOI":"10.18632\/oncotarget.26015","volume":"9","author":"PA Regidor","year":"2018","unstructured":"Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9(77):34628\u201338. https:\/\/doi.org\/10.18632\/oncotarget.26015.","journal-title":"Oncotarget"},{"key":"3587_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.5114\/pm.2015.52154","volume":"2","author":"M Bi\u0144kowska","year":"2015","unstructured":"Bi\u0144kowska M, Woro\u0144 J. Progestogens in menopausal hormone therapy. Menopausal Rev. 2015;2:134\u201343. https:\/\/doi.org\/10.5114\/pm.2015.52154.","journal-title":"Menopausal Rev"},{"key":"3587_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jsbmb.2013.08.001","volume":"142","author":"JP Hapgood","year":"2014","unstructured":"Hapgood JP, Africander D, Louw R, Ray RM, Rohwer JM. Potency of progestogens used in hormonal therapy: toward understanding differential actions. J Steroid Biochem Mol Biol. 2014;142:39\u201347. https:\/\/doi.org\/10.1016\/j.jsbmb.2013.08.001.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"3587_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13643-022-02045-9","volume":"11","author":"N Borissov","year":"2022","unstructured":"Borissov N, Haas Q, Minder B, et al. Reducing systematic review burden using deduklick: a novel, automated, reliable, and explainable deduplication algorithm to foster medical research. Syst Rev. 2022;11(1):172. https:\/\/doi.org\/10.1186\/s13643-022-02045-9.","journal-title":"Syst Rev"},{"key":"3587_CR6","unstructured":"NIH Quality Assessment Tool for Controlled Intervention Studies. NIH Quality Assessment Tool for Controlled Intervention Studies - https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"issue":"6","key":"3587_CR7","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1152\/japplphysiol.00031.2005","volume":"98","author":"NS Stachenfeld","year":"2005","unstructured":"Stachenfeld NS, Taylor HS. Progesterone increases plasma volume independent of estradiol. J Appl Physiol. 2005;98(6):1991\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15718411.","journal-title":"J Appl Physiol"},{"issue":"1","key":"3587_CR8","first-page":"71","volume":"21","author":"AN Atallah","year":"1988","unstructured":"Atallah AN, Guimaraes JA, Gebara M, Sustovich DR, Martinez TR, Camano L. Progesterone increases glomerular filtration rate, urinary kallikrein excretion and uric acid clearance in normal women. Braz J Med Biol Res. 1988;21(1):71\u20134. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3179582.","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"3587_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-2003-41753","volume":"111","author":"PM Spritzer","year":"2003","unstructured":"Spritzer PM, Vitola D, Vilodre LC, et al. One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension. Exp Clin Endocrinol Diabetes. 2003;111(5):267\u201373. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12951632.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"3587_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1161\/01.HYP.33.5.1190","volume":"33","author":"EW Seely","year":"1999","unstructured":"Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension. 1999;33(5):1190\u20134. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10334810.","journal-title":"Hypertension"},{"issue":"6","key":"3587_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1159\/000168574","volume":"48","author":"L De Soldati","year":"1966","unstructured":"De Soldati L, De Forteza IE, Pellegatta CR, Cammarota H. The antihypertensive action of progesterone. Cardiologia. 1966;48(6):489\u2013503. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/5958560.","journal-title":"Cardiologia"},{"issue":"1","key":"3587_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/13697137.2010.491924","volume":"14","author":"DY Lee","year":"2011","unstructured":"Lee DY, Kim JY, Kim JH, et al. Effects of hormone therapy on ambulatory blood pressure in postmenopausal Korean women. Climacteric. 2011;14(1):92\u20139. https:\/\/doi.org\/10.3109\/13697137.2010.491924.","journal-title":"Climacteric"},{"issue":"5","key":"3587_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1161\/HYPERTENSIONAHA.108.126516","volume":"53","author":"JP Langrish","year":"2009","unstructured":"Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009;53(5):805\u201311. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.126516.","journal-title":"Hypertension"},{"key":"3587_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF02590008","volume":"197","author":"G Stark","year":"1962","unstructured":"Stark G. [The excretion of aldosterone, cortisone and cortisol and of sodium and potassium after large doses of progesterone]. Arch Gynakol. 1962;197:28\u201335. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/13916311.","journal-title":"Arch Gynakol"},{"issue":"4","key":"3587_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1530\/acta.0.0420537","volume":"42","author":"G Stark","year":"1963","unstructured":"Stark G, Kossmann H, DIE AUSSCHEIDUNG VON ALDOSTERON, NATRIUM UND KALIUM NACH FORTLAUFENDER HOHER PROGESTERONGABE. Acta Endocrinol. 1963;42(4):537. https:\/\/doi.org\/10.1530\/acta.0.0420537.","journal-title":"Acta Endocrinol"},{"key":"3587_CR16","first-page":"426","volume":"90","author":"M Plaza De Los Reyes","year":"1962","unstructured":"Plaza De Los Reyes M, Gomez R, Cruz-Coke R, et al. [The renal excretion of sodium, potassium and water in arterial hypertension. III. Effect of progesterone]. Rev Med Chil. 1962;90:426\u201330. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14487165.","journal-title":"Rev Med Chil"},{"issue":"1","key":"3587_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1046\/j.1365-2265.2003.01600.x","volume":"58","author":"AJ Proudler","year":"2003","unstructured":"Proudler AJ, Cooper A, Whitehead M, Stevenson JC. Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocrinol (Oxf). 2003;58(1):30\u20135. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12519409.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"3587_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/09513599009024975","volume":"4","author":"H Picolet","year":"1990","unstructured":"Picolet H, Girard P, Nemoz C, Boissel JP. Effects of dydrogesterone on hydroelectrolytic metabolism: a randomized double-blind study. Gynecol Endocrinol. 1990;4(4):219\u201324. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2082718.","journal-title":"Gynecol Endocrinol"},{"key":"3587_CR19","doi-asserted-by":"publisher","unstructured":"Sumino H, Ichikawa S, Kanda T et al. Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. 1999;12(10 I):1044\u20137. https:\/\/doi.org\/10.1016\/S0895-7061\/2899\/2900094-1","DOI":"10.1016\/S0895-7061\/2899\/2900094-1"},{"key":"3587_CR20","doi-asserted-by":"publisher","unstructured":"Nogawa N, Sumino H, Ichikawa S et al. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. 2001;8(3):210\u20135. https:\/\/doi.org\/10.1097\/00042192-200105000-00011","DOI":"10.1097\/00042192-200105000-00011"},{"key":"3587_CR21","doi-asserted-by":"publisher","unstructured":"Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. 2001;14(3):206\u201311. https:\/\/doi.org\/10.1016\/S0895-7061\/2800\/2901253-X","DOI":"10.1016\/S0895-7061\/2800\/2901253-X"},{"issue":"5","key":"3587_CR22","first-page":"327","volume":"3","author":"G Lelli","year":"1984","unstructured":"Lelli G, Angelelli B, Zanichelli L, et al. The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients. Chemioterapia. 1984;3(5):327\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6241849.","journal-title":"Chemioterapia"},{"key":"3587_CR23","doi-asserted-by":"crossref","unstructured":"Pang SC, Greendale GA, Cedars MI, et al. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril. 1993;59(1):76\u201382. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8419226.","DOI":"10.1016\/S0015-0282(16)55618-0"},{"issue":"7","key":"3587_CR24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.amjhyper.2005.10.006","volume":"19","author":"J Ichikawa","year":"2006","unstructured":"Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006;19(7):744\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16814131.","journal-title":"Am J Hypertens"},{"issue":"4","key":"3587_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1447-0594.2008.00474.x","volume":"8","author":"A Ichikawa","year":"2008","unstructured":"Ichikawa A, Sumino H, Ogawa T, Ichikawa S, Nitta K. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. Geriatr Gerontol Int. 2008;8(4):259\u201364. https:\/\/doi.org\/10.1111\/j.1447-0594.2008.00474.x.","journal-title":"Geriatr Gerontol Int"},{"issue":"1","key":"3587_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/080370500439380","volume":"9","author":"Paul Manwaring Litsa Morfis Terence Diamond Laurence GH","year":"2000","unstructured":"Paul Manwaring Litsa Morfis Terence Diamond Laurence GH. Effects of hormone replacement therapy on ambulatory blood pressure and vascular responses in normotensive women. Blood Press. 2000;9(1):22\u20137. https:\/\/doi.org\/10.1080\/080370500439380.","journal-title":"Blood Press"},{"issue":"1","key":"3587_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/gme.0000000000002086","volume":"30","author":"XZ Jiang","year":"2023","unstructured":"Jiang XZ, Aragaki AK, Nudy M, et al. The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the women\u2019s Health Initiative clinical trials. Menopause-J N Am Menopause Soc. 2023;30(1):28\u201336. https:\/\/doi.org\/10.1097\/gme.0000000000002086.","journal-title":"Menopause-J N Am Menopause Soc"},{"issue":"7","key":"3587_CR28","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1210\/jc.2016-3851","volume":"102","author":"AH Ahmed","year":"2017","unstructured":"Ahmed AH, Gordon RD, Ward G, et al. Effect of combined hormonal replacement therapy on the Aldosterone\/Renin Ratio in Postmenopausal Women. J Clin Endocrinol Metab. 2017;102(7):2329\u201334. https:\/\/doi.org\/10.1210\/jc.2016-3851.","journal-title":"J Clin Endocrinol Metab"},{"key":"3587_CR29","doi-asserted-by":"publisher","unstructured":"Zacharieva S, Shigarminova R, Nachev E et al. Ambulatory blood pressure monitonng and active renin in menopausal women treated with amlodipine and hormone replacement therapy. 2004;19(1):26\u201332. https:\/\/doi.org\/10.1080\/0951359042000196295","DOI":"10.1080\/0951359042000196295"},{"key":"3587_CR30","doi-asserted-by":"crossref","unstructured":"Crane MG, Harris JJ. Plasma renin activity and aldosterone excretion rate in normal subjects. II. Effect of oral contraceptive agents. J Clin Endocrinol Metab. 1969;29(4):558\u201362. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/5779248.","DOI":"10.1210\/jcem-29-4-558"},{"issue":"1","key":"3587_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000179429","volume":"15","author":"R Punnonen","year":"1981","unstructured":"Punnonen R, Lammintausta R, Viinamaki O. Effect of medroxyprogesterone acetate and d-norgestrel on plasma renin activity, antidiuretic hormone, and urinary aldosterone in postmenopausal women. Horm Res. 1981;15(1):1\u20136. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6460678.","journal-title":"Horm Res"},{"key":"3587_CR32","doi-asserted-by":"crossref","unstructured":"Bissonnette F, Lussier-Cacan S, Fugere P, Berube S. Metabolic effect of two hormonal preparations in postmenopausal women. Maturitas. 1997;27(3):275\u201384. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9288700.","DOI":"10.1016\/S0378-5122(97)00042-X"},{"key":"3587_CR33","unstructured":"Goretzlehner G, Nikschick S, Zimmermann T. Sequential hormone replacement therapy with estradiol valerate and chlormadinone acetate in the postmenopause. Effects on Kupperman-index, body weight, blood pressure, lipids, enzymes, and electrolytes. [German]. 1996;118(7):420\u20135. https:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS. https:\/\/libkey.io\/libraries\/528\/openurl?genre=article&aulast=Goretzlehner&issn=0044-4197&title=Zentralblatt+fur+Gynakologie&atitle=Der+Einfluss+von+Estradiolvalerat+un."},{"issue":"5","key":"3587_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0010-7824(88)90021-2","volume":"37","author":"AF Yu","year":"1988","unstructured":"Yu AF, Wu SX, Liu JL, et al. Metabolic changes in women using a long-acting monthly oral contraceptive and return of ovulation on discontinuation. Contraception. 1988;37(5):517\u201328. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2457468.","journal-title":"Contraception"},{"key":"3587_CR35","unstructured":"Wongwananuruk P, Panchalee C. Comparison of Body Weight Change during Contraception with Belara and Yasmin. Published online 2020. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02027952\/full"},{"key":"3587_CR36","unstructured":"Klinger G, Berg W, Schneider HJ, Stelzner A. Long term effects of hormonal contraceptives on 24 hr urinary excretion of sodium, potassium, calcium, magnesium, chloride, phosphate, sulfate, uric, oxalic and citric acids and lysozyme. [German]. 1979;72(6):393\u20138. https:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS. https:\/\/libkey.io\/libraries\/528\/openurl?genre=article&aulast=Klinger&issn=0044-3611&title=Zeitschrift+fur+Urologie+und+Nephrologie&atitle=UNTERSUCHUNGEN+ZUR+LANGZEITWIR."},{"key":"3587_CR37","doi-asserted-by":"crossref","unstructured":"Vexiau P, Fiet J, Conard J, et al. 17 beta-estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate. Fertil Steril. 1995;63(3):508\u201315. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7851579.","DOI":"10.1016\/S0015-0282(16)57418-4"},{"issue":"5\u20136","key":"3587_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000182166","volume":"36","author":"K Ohyama","year":"1991","unstructured":"Ohyama K, Fujimoto M, Nakagomi Y, Ohta M, Yamori T, Kato K. Effect of cyproterone acetate on active and inactive renin secretion in patients with precocious puberty and genetic short stature. Horm Res. 1991;36(5\u20136):216\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1840421.","journal-title":"Horm Res"},{"key":"3587_CR39","doi-asserted-by":"crossref","unstructured":"Zacharieva S, Kirilov G, Kalinov K, et al. Effect of different hormone replacement therapy regimens on circadian blood pressure profile and active renin in postmenopausal women. Gynecol Endocrinol. 2002;16(6):461\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12626033.","DOI":"10.1080\/713603160"},{"issue":"4","key":"3587_CR40","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","volume":"98","author":"SM Bhattacharya","year":"2012","unstructured":"Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98(4):1053\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.06.035.","journal-title":"Fertil Steril"},{"issue":"4","key":"3587_CR41","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1210\/jcem-73-4-837","volume":"73","author":"W Oelkers","year":"1991","unstructured":"Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab. 1991;73(4):837\u201342. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1890155.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3587_CR42","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.fertnstert.2009.10.016","volume":"94","author":"F Fruzzetti","year":"2010","unstructured":"Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR. Comparison of effects of 3\u00a0mg drospirenone plus 20 mug ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril. 2010;94(5):1793\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.10.016.","journal-title":"Fertil Steril"},{"key":"3587_CR43","doi-asserted-by":"publisher","unstructured":"Tremollieres FA, Pouilles JM, Ribot CA. A prospective two-year study of progestin given alone in postmenopausal women: Effect on lipid and metabolic parameters. 1995;173(1):85\u20139. https:\/\/doi.org\/10.1016\/0002-9378%2895%2990174-4","DOI":"10.1016\/0002-9378%2895%2990174-4"},{"key":"3587_CR44","doi-asserted-by":"crossref","unstructured":"Jenkins JS. Progesterone and norethisterone in cyclical oedema and ascites. Br Med J. 1961;2(5256):861\u20133. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/13789834.","DOI":"10.1136\/bmj.2.5256.861"},{"key":"3587_CR45","doi-asserted-by":"crossref","unstructured":"Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril. 1995;64(5):957-962. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7589641.","DOI":"10.1016\/S0015-0282(16)57909-6"},{"key":"3587_CR46","unstructured":"Beckerhoff R, Luetscher JA, Beckerhoff I, Nokes GW. Effects of oral contraceptives on the renin-angiotensin system and on blood pressure of normal young women. Johns Hopkins Med J. 1973;132(2):80\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4346163."},{"key":"3587_CR47","doi-asserted-by":"crossref","unstructured":"Beckerhoff R, Vetter W, Armbruster H, Luetscher JA, Siegenthaler W. Plasma-aldosterone during oral-contraceptive therapy. Lancet. 1973;1(7814):1218\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4122566.","DOI":"10.1016\/S0140-6736(73)90530-8"},{"key":"3587_CR48","doi-asserted-by":"crossref","unstructured":"Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet. 1995;346(8967):89\u201390. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7603219.","DOI":"10.1016\/S0140-6736(95)92114-1"},{"issue":"6","key":"3587_CR49","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2141.2004.04846.x","volume":"124","author":"JC Stevenson","year":"2004","unstructured":"Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol. 2004;124(6):802\u20138. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15009069.","journal-title":"Br J Haematol"},{"key":"3587_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.0954-6820.1981.tb02627.x","volume":"646","author":"M Brons","year":"1981","unstructured":"Brons M, Jacobsen JG, Kristoffersen K. Changes in plasma renin concentration, activity and substrate after twentyeight days\u2019 treatment with micronized estrogen, ethinylestradiol and norethisterone-acetate in postmenopausal women. Acta Med Scand Suppl. 1981;646:94\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7018189.","journal-title":"Acta Med Scand Suppl"},{"issue":"3","key":"3587_CR51","first-page":"109","volume":"77","author":"J Branczeisz","year":"1983","unstructured":"Branczeisz J, Hubl W, Freymann E, Sarembe B. [Effect of Deposiston on hormone secretion of the renin-aldosterone system, the adrenal cortex and the pituitary - ovary system]. Z Arztl Fortbild (Jena). 1983;77(3):109\u201311. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6344451.","journal-title":"Z Arztl Fortbild (Jena)"},{"key":"3587_CR52","first-page":"583","volume":"91","author":"I Bradford","year":"1963","unstructured":"Bradford I, Gomez RE, Generini G. [Effects of Norethisterone acetate on the Renal Excretion of Sodium, Potassium and Water in normal individuals]. Rev Med Chil. 1963;91:583\u20135. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14090114.","journal-title":"Rev Med Chil"},{"issue":"2","key":"3587_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejogrb.2009.09.004","volume":"147","author":"W Junge","year":"2009","unstructured":"Junge W, El-Samalouti V, Gerlinger C, Schaefers M. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. Eur J Obstet Gynecol Reprod Biol. 2009;147(2):195\u2013200. https:\/\/doi.org\/10.1016\/j.ejogrb.2009.09.004.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7","key":"3587_CR54","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/0002-9378(80)91052-2","volume":"136","author":"S Roy","year":"1980","unstructured":"Roy S, Mishell DR Jr., Gray G, et al. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. Am J Obstet Gynecol. 1980;136(7):920\u201331. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6767404.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"3587_CR55","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3109\/09513590.2014.1003294","volume":"31","author":"AM Paoletti","year":"2015","unstructured":"Paoletti AM, Cagnacci A, Di Carlo C, et al. Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study. Gynecol Endocrinol. 2015;31(5):384\u20137. https:\/\/doi.org\/10.3109\/09513590.2014.1003294.","journal-title":"Gynecol Endocrinol"},{"key":"3587_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/00016348209155314","volume":"105","author":"MH Briggs","year":"1982","unstructured":"Briggs MH, Briggs M. Randomized prospective studies on metabolic effects of oral contraceptives. Acta Obstet Gynecol Scand Suppl. 1982;105:25\u201332. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6805241.","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"3587_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1472-6904-11-23","volume":"11","author":"ST Bird","year":"2011","unstructured":"Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clin Pharml. 2011;11:23. https:\/\/doi.org\/10.1186\/1472-6904-11-23.","journal-title":"BMC Clin Pharml"},{"issue":"1","key":"3587_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/jcem-63-1-29","volume":"63","author":"F Elkik","year":"1986","unstructured":"Elkik F, Basdevant A, Jackanicz TM, et al. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel. J Clin Endocrinol Metab. 1986;63(1):29\u201335. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3086360.","journal-title":"J Clin Endocrinol Metab"},{"key":"3587_CR59","first-page":"50","volume":"202","author":"P Liukko","year":"1987","unstructured":"Liukko P, Erkkola R, Gronroos M, Lammintausta R. Plasma renin activity, blood pressure and body weight during two years\u2019 oral contraception with two different low-estrogen combinations. Ann Chir Gynaecol Suppl. 1987;202:50\u20133. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3310827.","journal-title":"Ann Chir Gynaecol Suppl"},{"issue":"3","key":"3587_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00004872-199603000-00010","volume":"14","author":"B Heintz","year":"1996","unstructured":"Heintz B, Schmauder C, Witte K, et al. Blood pressure rhythm and endocrine functions in normotensive women on oral contraceptives. J Hypertens. 1996;14(3):333\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8723987.","journal-title":"J Hypertens"},{"issue":"6","key":"3587_CR61","first-page":"1816","volume":"80","author":"W Oelkers","year":"1995","unstructured":"Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80(6):1816\u201321. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7775629.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3587_CR62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","volume":"103","author":"C Klipping","year":"2021","unstructured":"Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103(4):213\u201321. https:\/\/doi.org\/10.1016\/j.contraception.2021.01.001.","journal-title":"Contraception"},{"issue":"5","key":"3587_CR63","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0010-7824(03)00006-4","volume":"67","author":"I Wiegratz","year":"2003","unstructured":"Wiegratz I, Kutschera E, Lee JH, et al. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception. 2003;67(5):361\u20136. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12742558.","journal-title":"Contraception"},{"key":"3587_CR64","doi-asserted-by":"publisher","unstructured":"Odutayo A, Cherney D, Miller J et al. Transdermal contraception and the renin-angiotensin-aldosterone system in premenopausal women. 2015;308(6):F535\u201340. https:\/\/doi.org\/10.1152\/ajprenal.00602.2014","DOI":"10.1152\/ajprenal.00602.2014"},{"key":"3587_CR65","unstructured":"Soveri P, Fyhrquist F. Plasma renin activity and angiotensin II during oral contraception. Ann Clin Res. 1977;9(6):346\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/616222."},{"key":"3587_CR66","unstructured":"Moore C, Feichtinger W, Klinger G et al. Clinical findings with the dienogest-containing oral contraceptive Valette. 1999;35(SUPPL. C):53\u201368.\u00a0https:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed6&AN=29342747. https:\/\/libkey.io\/libraries\/528\/openurl?genre=article&aulast=Moore&issn=0025-7656&title=Drugs+of+Today&atitle=Clinical+findings+with+the+dienogest-containing+oral+cont."},{"key":"3587_CR67","doi-asserted-by":"publisher","unstructured":"Schindler AE, Henkel A, Moore C, Oettel M. Effect and safety of high-dose dienogest (20\u00a0mg\/day) in the treatment of women with endometriosis. Arch Gynecol Obstet. 2010;282(5):507\u201314. https:\/\/doi.org\/10.1007\/s00404-009-1301-z.","DOI":"10.1007\/s00404-009-1301-z"},{"issue":"5","key":"3587_CR68","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/0010-7824(88)90019-4","volume":"37","author":"G Hoppe","year":"1988","unstructured":"Hoppe G. Gestoden, an innovative progestogen. Contraception. 1988;37(5):493\u2013501. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3409702.","journal-title":"Contraception"},{"key":"3587_CR69","doi-asserted-by":"publisher","unstructured":"De Leo V, la Marca A, Morgante G, et al. Evaluation of plasma levels of renin-aldosterone and blood pressure in women over 35 years treated with new oral contraceptives. Contraception. 2001;64(3):145\u20138. https:\/\/doi.org\/10.1016\/s0010-7824(01)00237-2.","DOI":"10.1016\/s0010-7824(01)00237-2"},{"key":"3587_CR70","doi-asserted-by":"publisher","unstructured":"Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N. Effects of two combined oral contraceptives containing ethinyl estradiol 30 mu g combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet. 2009;280(2):255\u201361. https:\/\/doi.org\/10.1007\/s00404-008-0907-x.","DOI":"10.1007\/s00404-008-0907-x"},{"key":"3587_CR71","doi-asserted-by":"publisher","unstructured":"Pizzolo F, Raffaelli R, Memmo A, et al. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J Hypertens. 2010;28(1):135\u201342. https:\/\/doi.org\/10.1097\/HJH.0b013e32833266e3.","DOI":"10.1097\/HJH.0b013e32833266e3"},{"issue":"16\u201317","key":"3587_CR72","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.clinbiochem.2012.06.025","volume":"45","author":"Z Locsei","year":"2012","unstructured":"Locsei Z, Horvath D, Racz K, Szabolcs I, Kovacs GL, Toldy E. Progestin-dependent effect of oral contraceptives on plasma aldosterone\/renin ratio. Clin Biochem. 2012;45(16\u201317):1516\u20138. https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.06.025.","journal-title":"Clin Biochem"},{"issue":"6","key":"3587_CR73","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1210\/jc.2010-2918","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Effect of contraceptives on aldosterone\/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab. 2011;96(6):1797\u2013804. https:\/\/doi.org\/10.1210\/jc.2010-2918.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3587_CR74","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0010-7824(98)00113-9","volume":"58","author":"S Arangino","year":"1998","unstructured":"Arangino S, Cagnacci A, Angiolucci M, Longu G, Melis GB, Volpe A. Effect of desogestrel-containing oral contraceptives on vascular reactivity and catecholamine levels. Contraception. 1998;58(5):289\u201393. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9883384.","journal-title":"Contraception"},{"issue":"3","key":"3587_CR75","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3109\/09513590009167683","volume":"14","author":"W Oelkers","year":"2000","unstructured":"Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol. 2000;14(3):204\u201313. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10923282.","journal-title":"Gynecol Endocrinol"},{"issue":"5\u20136","key":"3587_CR76","first-page":"155","volume":"68","author":"P Liukko","year":"1979","unstructured":"Liukko P, Erkkola R, Lammintausta R. Effect of oral contraceptive containing a new progestin (ORG 2969) on plasma renin activity, growth hormone and immunoreactive insulin. Ann Chir Gynaecol. 1979;68(5\u20136):155\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/161858.","journal-title":"Ann Chir Gynaecol"},{"issue":"1","key":"3587_CR77","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.contraception.2003.08.014","volume":"69","author":"W Suthipongse","year":"2004","unstructured":"Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3\u00a0mg drospirenone\/30 mu g ethinylestradiol and 150 mu g levonogestrel\/30 mu g ethinylestradiol in Thai women. Contraception. 2004;69(1):23\u20136. https:\/\/doi.org\/10.1016\/j.contraception.2003.08.014.","journal-title":"Contraception"},{"issue":"5","key":"3587_CR78","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.contraception.2015.07.014","volume":"92","author":"DF Archer","year":"2015","unstructured":"Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92(5):439\u201344. https:\/\/doi.org\/10.1016\/j.contraception.2015.07.014.","journal-title":"Contraception"},{"issue":"13","key":"3587_CR79","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","volume":"112","author":"WB White","year":"2005","unstructured":"White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112(13):1979\u201384. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16186434.","journal-title":"Circulation"},{"issue":"2","key":"3587_CR80","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","volume":"48","author":"WB White","year":"2006","unstructured":"White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48(2):246\u201353. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16801478.","journal-title":"Hypertension"},{"issue":"3","key":"3587_CR81","first-page":"426","volume":"90","author":"S Taneepanichskul","year":"2007","unstructured":"Taneepanichskul S, Jaisamrarn U, Phupong V. Effect of a new oral contraceptive with drospirenone on vital signs, complete blood count, glucose, electrolytes, renal, and liver function. J Med Assoc Thai. 2007;90(3):426\u201331. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17427515.","journal-title":"J Med Assoc Thai"},{"issue":"6","key":"3587_CR82","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/0091270007300952","volume":"47","author":"B Schutt","year":"2007","unstructured":"Schutt B, Kunz M, Blode H. Coadministration of estradiol\/drospirenone and Indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. J Clin Pharmacol. 2007;47(6):774\u201381. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17463217.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"3587_CR83","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/0091270006289973","volume":"46","author":"R Schurmann","year":"2006","unstructured":"Schurmann R, Blode H, Benda N, Cronin M, Kufner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol. 2006;46(8):867\u201375. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16855071.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"3587_CR84","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.amjhyper.2004.12.003","volume":"18","author":"RA Preston","year":"2005","unstructured":"Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone\/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18(6):797\u2013804. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15925739.","journal-title":"Am J Hypertens"},{"issue":"3 Pt 1","key":"3587_CR85","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/01.gme.0000243572.63322.f7","volume":"14","author":"RA Preston","year":"2007","unstructured":"Preston RA, Norris PM, Alonso AB, Ni P, Hanes V, Karara AH. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause. 2007;14(3 Pt 1):408\u201314. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17224857.","journal-title":"Menopause"},{"issue":"9","key":"3587_CR86","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0895-7061(02)02980-1","volume":"15","author":"RA Preston","year":"2002","unstructured":"Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone\/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens. 2002;15(9):816\u201322. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12219878.","journal-title":"Am J Hypertens"},{"issue":"2","key":"3587_CR87","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","volume":"61","author":"KS Parsey","year":"2000","unstructured":"Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61(2):105\u201311. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10802275.","journal-title":"Contraception"},{"key":"3587_CR88","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejogrb.2014.01.006","volume":"175","author":"MG Nisenbaum","year":"2014","unstructured":"Nisenbaum MG, de Melo NR, Giribela CR, et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014;175:62\u20136. https:\/\/doi.org\/10.1016\/j.ejogrb.2014.01.006.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10","key":"3587_CR89","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1177\/0091270007306560","volume":"47","author":"AH Karara","year":"2007","unstructured":"Karara AH, Hanes V, Alonso A, et al. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women. J Clin Pharmacol. 2007;47(10):1292\u2013302. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17906162.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3587_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13625180008500375","volume":"5","author":"J Huber","year":"2000","unstructured":"Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5(1):25\u201334. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10836660.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"3587_CR91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.contraception.2011.08.017","volume":"86","author":"CR Giribela","year":"2012","unstructured":"Giribela CR, Melo NR, Silva RC, et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception. 2012;86(1):35\u201341. https:\/\/doi.org\/10.1016\/j.contraception.2011.08.017.","journal-title":"Contraception"},{"issue":"11","key":"3587_CR92","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3109\/09513590.2015.1062860","volume":"31","author":"CR Giribela","year":"2015","unstructured":"Giribela CR, Consolim-Colombo FM, Nisenbaum MG, et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3\u00a0mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015;31(11):912\u20135. https:\/\/doi.org\/10.3109\/09513590.2015.1062860.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"3587_CR93","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/13697137.2010.520099","volume":"14","author":"M Gambacciani","year":"2011","unstructured":"Gambacciani M, Rosano G, Cappagli B, Pepe A, Vitale C, Genazzani AR. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric. 2011;14(1):18\u201324. https:\/\/doi.org\/10.3109\/13697137.2010.520099.","journal-title":"Climacteric"},{"issue":"3","key":"3587_CR94","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.contraception.2006.10.011","volume":"75","author":"F Fruzzetti","year":"2007","unstructured":"Fruzzetti F, Lello S, Lazzarini V, et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3\u00a0mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception. 2007;75(3):199\u2013203. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17303489.","journal-title":"Contraception"},{"issue":"6","key":"3587_CR95","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4103\/ijmr.IJMR_478_20","volume":"154","author":"A Dogo","year":"2021","unstructured":"Dogo A, Dozic B, Vujovic S, Srebro D, Dozic I. Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women. Indian J Med Res. 2021;154(6):857\u201365. https:\/\/doi.org\/10.4103\/ijmr.IJMR_478_20.","journal-title":"Indian J Med Res"},{"issue":"6","key":"3587_CR96","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MBP.0000000000000139","volume":"20","author":"MN de Nadai","year":"2015","unstructured":"de Nadai MN, Nobre F, Ferriani RA, Vieira CS. Effects of two contraceptives containing drospirenone on blood pressure in normotensive women: a randomized-controlled trial. Blood Press Monit. 2015;20(6):310\u20135. https:\/\/doi.org\/10.1097\/MBP.0000000000000139.","journal-title":"Blood Press Monit"},{"key":"3587_CR97","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejogrb.2014.09.006","volume":"182","author":"TL de Morais","year":"2014","unstructured":"de Morais TL, Giribela C, Nisenbaum MG, et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol. 2014;182:113\u20137. https:\/\/doi.org\/10.1016\/j.ejogrb.2014.09.006.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"3587_CR98","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.contraception.2005.10.016","volume":"74","author":"LE Borges","year":"2006","unstructured":"Borges LE, Andrade RP, Aldrighi JM, et al. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3\u00a0mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception. 2006;74(6):446\u201350. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17157100.","journal-title":"Contraception"},{"key":"3587_CR99","unstructured":"Bayer. Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30\u00a0mg\/DRSP 3\u00a0mg) on Quality of Life. Published online 2002."},{"key":"3587_CR100","unstructured":"Bayer. Effect of Angeliq on blood pressure (BP) in postmenopausal hypertensive women. Published online 2004."},{"key":"3587_CR101","doi-asserted-by":"publisher","unstructured":"Kimble T, Burke AE, Barnhart KT, Archer DF, Colli E, Westhoff CL. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4\u00a0mg using a 24\/4-day regimen. 2020;2 (no pagination). https:\/\/doi.org\/10.1016\/j.conx.2020.100020","DOI":"10.1016\/j.conx.2020.100020"},{"key":"3587_CR102","doi-asserted-by":"publisher","unstructured":"Chen MJ, Jensen JT, Kaunitz AM et al. Tolerability and safety of the estetrol\/drospirenone combined oral contraceptive: pooled analysis of two multicenter, open-label phase 3 trials. 2022;116:44\u201350. https:\/\/doi.org\/10.1016\/j.contraception.2022.10.004","DOI":"10.1016\/j.contraception.2022.10.004"},{"key":"3587_CR103","unstructured":"Bayer. Effects of Angeliq and Prempro on blood pressure and Sodium Sensitivity in Postmenopausal Women with Prehypertension. Published online 2007."},{"key":"3587_CR104","doi-asserted-by":"publisher","unstructured":"Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol\/drospirenone and other oral contraceptives. Contraception. 2008;78(5):377\u201383. https:\/\/doi.org\/10.1016\/j.contraception.2008.06.012.","DOI":"10.1016\/j.contraception.2008.06.012"},{"key":"3587_CR105","doi-asserted-by":"publisher","unstructured":"Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception. 1995;51(2):99\u2013110. https:\/\/doi.org\/10.1016\/0010-7824(94)00015-O.","DOI":"10.1016\/0010-7824(94)00015-O"},{"key":"3587_CR106","doi-asserted-by":"publisher","unstructured":"Harvey PJ, Morris BL, Miller JA, Floras JS. Estradiol induces discordant angiotensin and blood pressure responses to Orthostasis in Healthy Postmenopausal women. Hypertension. 2005;45(3):399\u2013405. https:\/\/doi.org\/10.1161\/01.HYP.0000157161.78721.5c.","DOI":"10.1161\/01.HYP.0000157161.78721.5c"},{"key":"3587_CR107","doi-asserted-by":"publisher","unstructured":"Stanczyk FZ, Hapgood JP, Winer S, Mishell DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and Clinical effects. Endocr Rev. 2013;34(2):171\u2013208. https:\/\/doi.org\/10.1210\/er.2012-1008.","DOI":"10.1210\/er.2012-1008"},{"key":"3587_CR108","doi-asserted-by":"publisher","unstructured":"Hague S, MacKenzie IZ, Bicknell R, Rees MCP. In-vivo angiogenesis and progestogens. Hum Reprod. 2002;17(3):786\u201393. https:\/\/doi.org\/10.1093\/humrep\/17.3.786.","DOI":"10.1093\/humrep\/17.3.786"},{"key":"3587_CR109","doi-asserted-by":"publisher","unstructured":"Cutini PH, Massheimer VL. In vitro effects of progesterone and the synthetic progestin medroxyprogesterone acetate on vascular remodeling. Mol Cell Endocrinol. 2019;498:110543. https:\/\/doi.org\/10.1016\/j.mce.2019.110543.","DOI":"10.1016\/j.mce.2019.110543"},{"key":"3587_CR110","doi-asserted-by":"publisher","unstructured":"Vitale C, Mammi C, Gambacciani M, et al. Effect of hormone replacement therapy with the anti-mineralocorticoid progestin drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women. Int J Cardiol. 2017;227:217\u201321. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.149.","DOI":"10.1016\/j.ijcard.2016.11.149"},{"key":"3587_CR111","doi-asserted-by":"publisher","unstructured":"Piani F, Baffoni L, Strocchi E, Borghi C. Gender-specific medicine in the European Society of Cardiology Guidelines from 2018 to 2023: where are we going? J Clin Med. 2024;13(14):4026. https:\/\/doi.org\/10.3390\/jcm13144026.","DOI":"10.3390\/jcm13144026"},{"key":"3587_CR112","doi-asserted-by":"publisher","unstructured":"Kaemmle LM, Stadler A, Janka H, von Wolff M, Stute P. The impact of micronized progesterone on cardiovascular events \u2013 a systematic review. Climacteric. 2022;25(4):327\u201336. https:\/\/doi.org\/10.1080\/13697137.2021.2022644.","DOI":"10.1080\/13697137.2021.2022644"},{"key":"3587_CR113","doi-asserted-by":"publisher","unstructured":"Panay N, Nappi RE, Stute P, et al. Oral estradiol\/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens\/medroxyprogesterone acetate in real-world practice. Maturitas. 2023;172:23\u201331. https:\/\/doi.org\/10.1016\/j.maturitas.2023.04.004.","DOI":"10.1016\/j.maturitas.2023.04.004"},{"issue":"5","key":"3587_CR114","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1345\/aph.1M649","volume":"44","author":"N Sehovic","year":"2010","unstructured":"Sehovic N, Smith KP. Risk of venous thromboembolism with drospirenone in combined oral Contraceptive products. Ann Pharmacother. 2010;44(5):898\u2013903. https:\/\/doi.org\/10.1345\/aph.1M649.","journal-title":"Ann Pharmacother"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03587-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-03587-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03587-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T04:23:14Z","timestamp":1740198194000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-025-03587-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3587"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-03587-5","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}